Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease (CHD) with LDL-C above 70 mg/dL or 100 mg/dL depending on their CHD risk category~Exclusion Criteria:~* A condition which, in the opinion of the investigator, pose a risk to the patient or interfere with participating in the study~* Patient is likely to be greater than 20% noncompliant in taking study medications~* Patients with chronic medical conditions~* Patients with unstable doses of medications~* Pregnant or lactating women, women intending to become pregnant~* Patient is currently receiving prescription therapy with statins or other lipid-altering medications~* Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Arm 1: drug + comparator + Placebo
- 2 (Type: OTHER): Arm 2: drug + comparator + Placebo
- 3 (Type: OTHER): Arm 3: drug + comparator + Placebo
- 4 (Type: OTHER): Arm 4: drug + comparator + Placebo
- 5 (Type: OTHER): Arm 5: drug + comparator + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).